Immunotherapy in antiphospholipid syndrome

International Immunopharmacology

Volumn 27, Issue 2, 2015, Pages 200-208

  Lopez Pedrera, Ch ^a   Aguirre, M A ^a   Ruiz Limon, P ^a   Perez Sanchez C ^a   Jimenez Gomez, Y ^a   Barbarroja, N ^a   Cuadrado, M J ^b  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Antiphospholipid syndrome; New therapeutic approaches; Pathogenesis

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA2 GLYCOPROTEIN 1; FIBRINOGEN RECEPTOR ANTAGONIST; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; THROMBOPLASTIN; UBIDECARENONE; BIOLOGICAL PRODUCT; RITUXIMAB; UBIQUINONE;

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; ATHEROGENESIS; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOTHERAPY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CONFORMATION; THROMBOCYTE ACTIVATION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY; METABOLISM;

ANIMALS; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; BIOLOGICAL PRODUCTS; HUMANS; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOTHERAPY; RITUXIMAB; THROMBOPLASTIN; UBIQUINONE;

EID: 84937162679     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2015.06.006     Document Type: Article

References (118)

1. M.J. Cuadrado, C. Lopez-Pedrera, M.A. Khamashta, and et al. Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression Arthritis Rheum. 40 1997 834 841
2. P.M. Dobado-Berrios, Ch. Lopez-Pedrera, F. Velasco, and et al. Increased levels of tissue factor mRNA in mononuclear blood cells of patients with primary antiphospholipid syndrome Thromb. Haemost. 82 1999 1578 1582
3. P.M. Dobado-Berrios, Ch. Lopez-Pedrera, F. Velasco, and M.J. Cuadrado The role of TF in the antiphospholipid syndrome Arthritis Rheum. 44 2001 2467 2476
4. Ch. López-Pedrera, P. Buendía, M.J. Cuadrado, and et al. Antiphospho-lipid antibodies from antiphospholipid syndrome patients induce monocyte expression through the simultaneous activation of both NFkB/Rel proteins via p38 MAPK pathway, and the MEK1/ERK pathway Arthritis Rheum. 54 2006 301 311
5. M. Vega-Ostertag, E.N. Harris, and S.S. Pierangeli Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin Arthritis Rheum. 50 2004 2911 2919
6. M. Bohgaki, T. Atsumi, Y. Yamashita, and et al. The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-beta2 glycoprotein I antibodies Int. Immunol. 16 2004 1633 1641
7. G. Montiel-Manzano, Z. Romay-Penabad, E. Papalardo de Martinez, and et al. In vivo effects of an inhibitor of nuclear factor-kappa B on thrombogenic properties of antiphospholipid antibodies Ann. N. Y. Acad. Sci. 1108 2007 540 553
8. S. Dunoyer-Geindre, P. de Moerloose, B. Galve-de Rochemonteix, and et al. NFkappa B is an essential intermediate in the activation of endothelial cells by anti-beta(2)-glycoprotein 1 antibodies Thromb. Haemost. 88 2002 851 857
9. M. Vega-Ostertag, K. Casper, R. Swerlick, and et al. Involvement of p38 MAPK in the upregulation of tissue factor on endothelial cells by antiphospholipid antibodies Arthritis Rheum. 52 2005 1545 1554
10. H.F. Dvorak Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy J. Clin. Oncol. 20 2002 4368 4380
11. F.M.K. Williams, K. Parmar, G.R.V. Hughes, and B.J. Hunt Systemic endothelial cell markers in primary antiphospholipid syndrome Thromb. Haemost. 84 2000 742 746
12. M.J. Cuadrado, P. Buendía, F. Velasco, and et al. Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndrome J. Thromb. Haemost. 4 2006 2461 2469
13. C. López-Pedrera, M.A. Aguirre, P. Buendía, and et al. Differential expression of protease activated receptors in monocytes from patients with primary antiphospholipid syndrome Arthritis Rheum. 62 2010 869 877
14. C. López-Pedrera, M.J. Cuadrado, V. Hernández, and et al. Proteomic analysis in monocytes of antiphospholipid syndrome patients: deregulation of proteins related to the development of thrombosis Arthritis Rheum. 58 2008 2835 2844
15. N.J. Goulding, J. Dixey, E.F. Morand, R.A. Dodds, L.S. Wilkinson, A.A. Pitsillides, and et al. Differential distribution of annexins-I, -II, -IV, and -VI in synovium Ann. Rheum. Dis. 54 1995 841 845
16. D.J. Falcone, W. Borth, K.M. Faisal Khan, and K.A. Hajjar Plasminogen mediated matrix invasion and degradation by macrophages is dependent on surface expression of annexin II Blood 97 2001 777 784
17. J. Ahamed, H.H. Versteeg, M. Kerver, V.M. Chen, B.M. Mueller, P.J. Hogg, and et al. Disulfide isomerization switches TF from coagulation to cell signaling Proc. Natl. Acad. Sci. U. S. A. 103 2006 13932 13937
18. T. Higuchi, Y. Watanabe, and I. Waga Protein disulfide isomerase suppresses the transcriptional activity of NFkB Biochem. Biophys. Res. Commun. 318 2004 46 52
19. J. George, D. Harats, B. Gilburd, and et al. Immunolocalization of beta2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression Circulation 99 1999 2227 2230
20. Y. Shoenfeld, Y. Sherer, J. George, and D. Harats Autoantibodies associated with atherosclerosis Ann. Med. 32 2000 37 40
21. L.J. Jara, G. Medina, and O. Vera-Lastra Systemic antiphospholipid syndrome and atherosclerosis Clin. Rev. Allergy Immunol. 32 2007 172 177
22. P. Soltész, K. Veres, G. Lakos, E. Kiss, L. Muszbek, and G. Szegedi Evaluation of clinical and laboratory features of antiphospholipid syndrome: a retrospective study of 637 patients Lupus 12 4 2003 302 307
23. S. Jimenez, M.A. García-Criado, D. Tassies, and et al. Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome Rheumatology 44 6 2005 756 761
24. Y. Hasunuma, E. Matsuura, Z. Makita, T. Katahira, S. Nishi, and T. Koike Involvement of beta2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages Clin. Exp. Immunol. 107 3 1997 569 573
25. O. Vaarala Antiphospholipid antibodies and atherosclerosis Lupus 5 5 1996 442 447
26. K. Veres, G. Lakos, A. Kerenyi, and et al. Antiphospholipid antibodies in acute coronary syndrome Lupus 13 6 2004 423 427
27. M. Cugno, M.O. Borghi, L.M. Lonati, and et al. Patients with antiphospholipid syndrome display endothelial perturbation J. Autoimmun. 34 2 2010 105 110
28. P.R.J. Ames, I. Antionolfi, G. Scenna, G. Gaeta, M. Margagliones, and A. Margarita Atherosclerosis in thrombotic primary antiphospholipid syndrome J. Thromb. Haemost. 7 4 2009 537 542
29. C. Perez-Sanchez, P. Ruiz-Limon, M.A. Aguirre, M.L. Bertolaccini, M.A. Khamashta, A. Rodriguez-Ariza, and et al. Mitochondrial dysfunction in antiphospholipid syndrome: implications in the pathogenesis of the disease and effects of coenzyme Q(10) treatment Blood 119 24 Jun 14 2012 5859 5870
30. P.R. Ames, A. Margarita, J. Delgado Alves, C. Tommasino, L. Iannaccone, and V. Brancaccio Anticardiolipin antibody titre and plasma homocysteine level independently predict intima media thickness of carotid arteries in subjects with idiopathic antiphospholipid antibodies Lupus 11 4 2002 208 214
31. P.R. Ames, A. Margarita, K.B. Sokoll, M. Weston, and V. Brancaccio Premature atherosclerosis in primary antiphospholipid syndrome: preliminary data Ann. Rheum. Dis. 64 2 2005 315 317
32. A. Margarita, J. Batuca, G. Scenna, and et al. Subclinical atherosclerosis in primary antiphospholipid syndrome Ann. N. Y. Acad. Sci. 1108 2007 475 480
33. D. Shah, A. Wanchu, and A. Bhatnagar Interaction between oxidative stress and chemokines: possible pathogenic role in systemic lupus erythematosus and rheumatoid arthritis Immunobiology 216 9 2011 1010 1017
34. A.D. Luster Chemokines-chemotactic cytokines that mediate inflammation N. Engl. J. Med. 338 7 1998 436 445
35. K. Marutsuka, K. Hatakeyama, A. Yamashita, and Y. Asada Role of thrombogenic factors in the development of atherosclerosis J. Atheroscler. Thromb. 12 1 2005 1 8
36. A. Perl Pathogenic mechanisms in systemic lupus erythematosus Autoimmunity 43 1 2010 1 6
37. J.D. Alves, and B. Grima Oxidative stress in systemic lupus erythematosus and antiphospholipid syndrome: a gateway to atherosclerosis Curr. Rheumatol. Rep. 5 5 2003 383 390
38. J.D. Morrow, and L.J. Roberts The isoprostanes. Current knowledge and directions for future research Biochem. Pharmacol. 51 1 1996 1 9
39. L. Iuliano, D. Practico, D. Ferro, and et al. Enhanced lipid peroxidation in patients positive for antiphospholipid antibodies Blood 90 10 1997 3931 3935
40. M. Charakida, C. Besler, J.R. Batuca, and et al. Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome JAMA 302 11 2009 1210 1217
41. N. Prinz, N. Clemens, D. Strand, and et al. Antiphospholipid antibodies induce translocation of TLR7 and TLR8 to the endosome in human monocytes and plasmacytoid dendritic cells Blood 118 2011 2322 2332
42. CONFORMATIONS OF B2GPI B. Giannakopoulos, and A. Krilis The pathogenesis of the Antiphospholipid syndrome N. Engl. J. Med. 368 2013 1033 1044
43. Y. Ioannou, J.Y. Zhang, M. Qi, L. Gao, J.C. Qi, D.M. Yu, and et al. Novel assays of thrombogenic pathogenicity in the antiphospholipid syndrome based on the detection of molecular oxidative modification of the major autoantigen β2-glycoprotein I Arthritis Rheum. 63 2011 2774 2782
44. C. Agar, G.M. van Os, M. Morgelin, and et al. Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome Blood 116 2010 1336 1343
45. R.T. Urbanus, M.T. Pennings, R.H. Derksen, and P.G. de Groot Platelet activation by dimeric beta2-glycoprotein I requires signalling via both glycoprotein Ibalpha and apolipoprotein E receptor 2′ J. Thromb. Haemost. 6 2008 1405 1412
46. T. Shi, B. Giannakopoulos, X. Yan, and et al. Anti-beta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V Arthritis Rheum. 54 2006 2558 2567
47. M.P. Sikara, J.G. Routsias, M. Samiotaki, G. Panayotou, H.M. Moutsopoulos, and P.G. Vlachoyiannopoulos {beta}2 Glycoprotein I ({beta}2GPI) binds platelet factor 4 (PF4): implications for the pathogenesis of antiphospholipid syndrome Blood 115 3 Jan 21 2010 713 723
48. V. Proulle, R.A. Furie, G. Merrill-Skoloff, B.C. Furie, and B. Furie Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS Blood 124 4 Jul 24 2014 611 622
49. G. Ruiz-Irastorza, M. Crowther, W. Branch, and M.A. Khamashta Antiphospholipid syndrome Lancet 376 2010 1498 1509
50. S.S. Pierangeli, G. Girardi, M. Vega-Ostertag, and et al. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia Arthritis Rheum. 52 2005 2120 2124
51. G. Girardi, P. Redecha, and J.E. Salmon Heparin prevents antiphospho-lipid antibody-induced fetal loss by inhibiting complement activation Nat. Med. 10 2004 1222 1226
52. S.S. Pierangeli, P.P. Chen, E. Raschi, and et al. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms Semin. Thromb. Hemost. 34 2008 236 250
53. S. Stone, M.A. Khamashta, and L. Poston Placentation, antiphospholipid syndrome and pregnancy outcome Lupus 10 2001 67 74
54. N. Di Simone, M.P. Luigi, D. Marco, and et al. Pregnancies complicated with antiphospholipid syndrome: the pathogenic mechanism of antiphospholipid antibodies: a review of the literature Ann. N. Y. Acad. Sci. 1108 2007 505 514
55. L.W. Chamley, J.L. Allen, and P.M. Johnson Synthesis of beta2 glycoprotein 1 by the human placenta Placenta 18 1997 403 410
56. N. Di Simone, E. Raschi, C. Testoni, and et al. Pathogenic role of anti-beta 2-glycoprotein I antibodies in antiphospholipid associated fetal loss: characterisation of beta 2-glycoprotein I binding to trophoblast cells and functional effects of anti-beta 2-glycoprotein I antibodies in vitro Ann. Rheum. Dis. 64 2005 462 467
57. M.J. Mulla, J.J. Brosens, L.W. Chamley, and et al. Antiphospholipid antibodies induce a pro-inflammatory response in first trimester trophoblast via the TLR4/MyD88 pathway Am. J. Reprod. Immunol. 62 2009 96 111
58. D. Erkan, C.L. Aguiar, A. Andrade, H. Cohen, M.J. Cuadrado, A. Danowski, and et al. 14th International Congress on Antiphospholipid antibodies task force report on Antiphospholipid syndrome treatment trends Autoimmun. Rev. 13 2014 685 696
59. G. Agnelli, H.R. Buller, A. Cohen, M. Curto, A.S. Gallus, M. Johnson, and et al. Oral apixaban for the treatment of acute venous thromboembolism N. Engl. J. Med. 368 2013 799 808
60. EINSTEIN Investigators, R. Bauersachs, S.D. Berkowitz, B. Brenner, H.R. Buller, H. Decousus, and et al. Oral rivaroxaban for symptomatic venous thromboembolism (and supplementary appendix) N. Engl. J. Med. 363 2010 2499 2510
61. Investigators Hokusai-VTE, H.R. Büller, H. Décousus, M.A. Grosso, M. Mercuri, S. Middeldorp, and et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism N. Engl. J. Med. 369 2013 1406 1415
62. Summary of product characteristics (SPC), EU. Xarelto 10 mg film-coated tablets. Bayer HealthCare AG. Date of first authorization: 09/30/2008. Date of renewal of authorization: 05/22/2013. Date of revision of text: 06/2013 Available from: http://www.medicines.org.uk/emc/medicine/21265/SPC/Xarelto+10+mg+filmcoated+tablets
63. M. Petri Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients Curr. Rheumatol. Rep. 13 2011 77 80
64. M.H. Edwards, S. Pierangeli, X. Liu, J.H. Barker, G. Anderson, and E.N. Harris Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice Circulation 96 1997 4380 4384
65. J.H. Rand, X.X. Wu, A.S. Quinn, P.P. Chen, J.J. Hathcock, and D.J. Taatjes Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers Blood 112 2008 1687 1695
66. J.H. Rand, X.X. Wu, A.S. Quinn, A.W. Ashton, P.P. Chen, J.J. Hathcock, and et al. Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug Blood 115 2010 2292 2299
67. X.X. Wu, S. Guller, and J.H. Rand Hydroxychloroquine reduces binding of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5 expression Am. J. Obstet. Gynecol. 205 576 2011 e7 e14
68. K. Sacre, L.A. Criswell, and J.M. Mc Cune Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus Arthritis Res. Ther. 14 2012 R155
69. C.R. Albert, W.J. Schlesinger, and C.A. Viall Effect of hydroxychloroquine on antiphospholipid antibody-induced changes in first trimester trophoblast function Am. J. Reprod. Immunol. 71 2014 154 164
70. A. Schmidt-Tanguy, J. Voswinkel, D. Henrion, J.F. Subra, L. Loufrani, V. Rohmer, N. Ifrah, and C. Belizna Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients J. Thromb. Haemost. 11 10 Oct 2013 1927 1929
71. Hydroxychloroquine for the First Thrombosis Prevention in Antiphospholipid Antibody Positive Patients Feb 3 2013 IRSCTN NCT01784523
72. A. Undas, E. Brummel-Ziedins, and K.G. Mann Statins and blood coagulation Arterioscler. Thromb. Vasc. Biol. 25 2005 1 8
73. A. Undas, M. Celiska-Lowenhoff, M. Kaczor, and J. Musial New nonlipid effects of statins and their clinical relevance in cardiovascular disease Thromb. Haemost. 91 2004 1065 1077
74. R. Krysiak, B. Okopien, and Z.S. Herman Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes Drugs 63 2003 1821 1854
75. P.L. Meroni, E. Raschi, C. Testoni, and et al. Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype Arthritis Rheum. 44 2001 2870 2878
76. D.E. Ferrara, X. Liu, R.G. Espinola, and et al. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model Arthritis Rheum. 48 2003 3272 3279
77. D.E. Ferrara, R. Swerlick, K. Casper, and et al. Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid anti-bodies on endothelial cells J. Thromb. Haemost. 2 2004 1558 1563
78. L.A. Martínez, M.C. Amigo, A. Orozco, and et al. Effect of rosuvastatin on VCAM-1 expression by HUVEC exposed to APS serum in an in vitro model Clin. Exp. Rheumatol. 25 2007 18 19
79. C. López-Pedrera, P. Ruiz-Limón, M.A. Aguirre, and et al. Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome Ann. Rheum. Dis. 70 2011 675 682
80. P. Redecha, C.W. Franzke, W. Ruf, and et al. Neutrophil activation by the tissue factor/factor VIIa/PAR2 axis mediates foetal death in a mouse model of antiphospholipid syndrome J. Clin. Invest. 118 2008 3453 3461
81. P. Redecha, N. van Rooijen, D. Torry, and G. Girardi Pravastatin prevents miscarriages in mice: role of tissue factor in placental and foetal injury Blood 113 2009 4101 4109
82. P. Jajoria, V. Murthy, E. Papalardo, and et al. Statins for the treatment of antiphospholipid syndrome? Ann. N. Y. Acad. Sci. 1173 2009 736 745
83. P.M. Ridker, E. Danielson, and F.A. Fonseca Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N. Engl. J. Med. 20 2008 2195 2207
84. M. Turunen, J. Olsson, and G. Dallner Metabolism and function of coenzyme Q Biochim. Biophys. Acta 1660 1-2 2004 171 199
85. S.B. Ong, S. Subrayan, S.Y. Lim, D.M. Yellon, S.M. Davidson, and D.J. Hausenloy Inhibiting mitochondrial fission protects the heart against ischemia/ reperfusion injury Circulation 121 18 2010 2012 2022
86. P. Youinou, and Y. Reneaudineau The antiphospholipid syndrome as a model for B cell-induced autoimmune diseases Thromb. Res. 114 2004 363 369
87. S. Khattri, G. Zandman-Goddard, and E. Peeva B-cell directed therapies in antiphospholipid antibody syndrome - new directions based on murine and human data Autoimmun. Rev. 11 2012 717 722
88. P. Kahn, M. Ramanujman, R. Bethunaickan, W. Huang, H. Tao, M.P. Madaio, and et al. Prevention of murine antiphospholipid syndrome by BAFF blockade Arthritis Rheum. 58 2008 2824 2834
89. D. Kumar, and R.A.S. Roubey Use of rituximab in the antiphospholipid syndrome Curr. Rheumatol. Rep. 12 2010 40 44
90. E. Rubenstein, D.G. Arkfeld, S. Metyas, S. Shinada, S. Ehresmann, and H.A. Liebman Rituximab treatment for resistant antiphospholipid syndrome J. Rheumatol. 33 2006 355 357
91. F. Tenedios, D. Erkan, and M.D. Lockshin Rituximab in the Primary Antiphospholipid Syndrome (PAPS) Arthritis Rheum. 52 2005 4078
92. S. Sciascia, C. Naretto, D. Rossi, M. Bazzan, and D. Roccatello Treatment-induced downregulation of antiphospholipid antibodies: effect of rituximab alone on clinical and laboratory features of antiphospholipid syndrome Lupus 20 2011 1106 1108
93. R. Trappe, A. Loew, P. Thuss-Patience, B. Dorken, and H. Riess Successful treatment of thrombocytopenia in primary antiphospholipid antibody syndrome with the anti-CD20 antibody rituximab - monitoring of antiphospholipid and anti-GP antibodies: a case report Ann. Hematol. 85 2006 134 135
94. R. Costa, S. Fazal, R.B. Kaplan, J. Spero, and R. Costa Successful plasma exchange combined with rituximab therapy in aggressive APS-related cutaneous necrosis Clin. Rheumatol. 32 Suppl. 1 2013 S79 S82 10.1007/s10067-010-1506-3
95. G. Tsagalis, E. Psimenou, L. Nakopoulou, and A. Laggouranis Combination treatment with plasmapheresis and rituximab for recurrent focal segmental glomerulosclerosis after renal transplantation Artif. Organs 35 2011 420 425
96. H. Berman, I. Rodríguez-Pintó, R. Cervera, N. Morel, N. Costedoat-Chalumeau, D. Erkan, and et al. Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group (European Forum on Antiphospholipid Antibodies). Rituximab use in the catastrophic antiphospholipid syndrome: Descriptive analysis of the CAPS registry patients receiving rituximab Autoimmun. Rev. 12 2013 1085 1090 10.1016/j.autrev.2013.05.004
97. D. Erkan, J. Vega, G. Ramon, E. Kozora, and M.D. Lockshin Rituximab in antiphospholipid syndrome (RITAPS) - a pilot open-label phase II prospective trial for non-criteria manifestations of antiphospholipid antibodies Arthritis Rheum. 65 2013 464 471
98. J. Bakshi, and R. Stevens Rituximab therapy for recurrent thromboembolic disease in antiphospholipid syndrome Lupus 22 2013 865 867
99. K. Oku, O. Amengual, and T. Atsumi Pathophysiology of thrombosis and pregnancy morbidity in the antiphospholipid syndrome Eur. J. Clin. Investig. 42 10 Oct 2012 1126 1135
100. G. Girardi, J. Berman, P. Redecha, L. Spruce, J.M. Thurman, D. Kraus, and et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome J. Clin. Invest. 112 2003 1644 1654
101. P. Redecha, R. Tiley, M. Tencati, J.E. Salmon, D. Kirchhofer, N. Mackman, and et al. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury Blood 110 2007 2423 2431
102. S.S. Pierangeli, M. Vega-Ostertag, X. Liu, and G. Girardi Complement activation: a novel pathogenic mechanism in the antiphospholipid syndrome Ann. N. Y. Acad. Sci. 1051 2005 413 420
103. B.E. Lonze, A.L. Singer, and R.A. Montgomery Eculizumab and renal transplantation in a patient with CAPS N. Engl. J. Med. 362 2010 1744 1745
104. I. Shapira, D. Andrade, S.L. Allen, and J.E. Salmon Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab Arthritis Rheum. 64 2012 2719 2723
105. R. Khianey, S. Mushin, and D. Erkan Discordant aPTT and anti-FXa values in a catastrophic antiphospholipid syndrome patient receiving intravenous unfractionated heparin APLA-LACA 2013 (Abstract)
106. Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS) (PROMISSE) Accession date 05/01/2014 ClinicalTrials.gov Identifier: NCT00198068 Sep 12, 2005
107. J.E. Salmon, G. Girardi, and E. Theodore Woodward Award: antiphospholipid syndrome revisited: a disorder initiated by inflammation Trans. Am. Clin. Climatol. Assoc. 118 2007 99 114
108. D. Erkan, and M.D. Lockshin New approaches for managing antiphospholipid syndrome Nat. Clin. Pract. Rheumatol. 5 3 Mar 2009 160 170
109. S.S. Pierangeli, M. Vega-Ostertag, and E.N. Harris Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells: a pathway to targeted therapies Thromb. Res. 114 2004 467 476
110. S.S. Pierangeli, M.E. Vega-Ostertag, and E.B. González New targeted therapies for treatment of thrombosis in antiphospholipid syndrome Expert Rev. Mol. Med. 9 2007 1 15
111. A. Straub, H.P. Wendel, R. Azevedo, and G. Ziemer The GP IIb/IIIa inhibitor abciximab (ReoPro) decreases activation and interaction of platelets and leukocytes during in vitro cardiopulmonary bypass simulation Eur. J. Cardiothorac. Surg. 27 2005 617 621
112. ESPRIT Study Group, P.H. Halkes, J. van Gijn, L.J. Kappelle, P.J. Koudstaal, and A. Algra Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial Lancet 367 2006 1665 1673
113. ACTIVE Investigators Effect of clopidogrel added to aspirin in patients with atrial fibrillation N. Engl. J. Med. 360 2009 2066 2078
114. H. Zhou, A.S. Wolberg, and R.A. Roubey Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep Blood 104 8 Oct 15 2004 2353 2358
115. E.W. Holy, and F.C. Tanner Tissue factor in cardiovascular disease pathophysiology and pharmacological intervention Adv. Pharmacol. 59 2010 259 292
116. Y. Ioannou, Z. Romay-Penabad, C. Pericleous, and et al. In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of beta2-glycoprotein I: proof of concept J. Thromb. Haemost. 7 2009 833 842
117. M.V. Ostertag, X. Liu, V. Henderson, and S.S. Pierangeli A peptide that mimics the Vth region of beta-2-glycoprotein I reverses antiphospholipid-mediated thrombosis in mice Lupus 15 2006 358 365
118. Y.M. de la Torre, F. Pregnolato, F. D'Amelio, C. Grossi, N. Di Simone, F. Pasqualini, and et al. Anti-phospholipid induced murine fetal loss: novel protective effect of a peptide targeting the beta2 glycoprotein I phospholipid-binding site. Implications for human fetal loss J. Autoimmun. 38 2012 J209 J215